Published online Apr 7, 2015. doi: 10.3748/wjg.v21.i13.4006
Peer-review started: November 3, 2014
First decision: November 26, 2014
Revised: December 10, 2014
Accepted: January 8, 2015
Article in press: January 8, 2015
Published online: April 7, 2015
AIM: To determine the association between rapid viral response and IL28B, IL28RA, IL10RB and MxA polymorphisms in the Chinese Han population.
METHODS: The study cohort consisted of 238 chronic hepatitis C patients treated with interferon (IFN)-α-2b and ribavirin. Six single nucleotide polymorphisms were genotyped using the ABI TaqMan allelic discrimination assay. Biochemical indices were measured at baseline. Serum hepatitis C virus (HCV) RNA was detected at weeks 0, 4, 12 and 24 of therapy.
RESULTS: Only IL28B rs12980275 was associated with treatment response in the Chinese Han population. Patients carrying AG/GG genotypes had a reduced rapid viral response compared with patients carrying the AA genotype (additive model: adjusted OR = 0.43, 95%CI: 0.24-0.75). It took less time for patients with the AA genotype to achieve a viral load < 500 copies/mL (log-rank test, P = 0.004). In addition, the protective effect of genotype AA was independent of baseline viral load. HCV genotype, and baseline white blood cell count, α-fetoprotein and viral load might also help predict treatment response. The area under the receiver-operating characteristic curve was 0.726.
CONCLUSION: IL28B rs12980275 AA genotype is a strong predictor of positive response to IFN therapy in Chinese Han patients with hepatitis C.
Core tip: The association between IL28B rs12980275 and viral response to pegylated-interferon (IFN) plus ribavirin treatment has been observed in Japanese patients, but rarely in Chinese patients. Because pegylated-IFN is more expensive, non-pegylated instead of pegylated IFN-α is more commonly used for chronic hepatitis C treatment in Chinese primary hospitals. Therefore, the role of IFN-λ-related genes in the response to non-pegylated IFN-α treatment should be established to help guide clinical decisions and improve cost-effectiveness.